Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 1/2 2Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1

Interventions

pembrolizumab 83Cyclophosphamide 55Specimen Handling 54Carboplatin 53fludarabine 44Nivolumab 43Magnetic Resonance Spectroscopy 43Gemcitabine 41Biopsy 40venetoclax 33Bevacizumab 33Dexamethasone 31Paclitaxel 29Pemetrexed 27Injections 27Cisplatin 27Docetaxel 26Azacitidine 22atezolizumab 21Rituximab 21Oxaliplatin 21Capecitabine 21Lenalidomide 20Ipilimumab 20Temozolomide 19Fulvestrant 19Cetuximab 19abemaciclib 18Fluorouracil 18Cytarabine 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × cabazitaxel × 90 days × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06085729 2026-04-02

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡